Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of CAStem Cell Injection for steroid-refractory acute graft-versus-host disease after allo-HSCT
ChiCTR2600133146Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CAStem cells in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Overall response rate of acute graft-versus-host disease at Day 28 after first dose and Overall response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
CAStem cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2600133146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133146.